Island Pharmaceuticals : to present at BIO International Convention

For personal use only

15 June 2022

ASX Announcement

Island to present at

BIO International Convention

MELBOURNE Australia, 15 June 2022: Australian mid-clinical stage antiviral drug

development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to advise that Island's CEO, Dr David Foster has been selected to present at the BIO International Convention in San Diego, California on Wednesday 15 June, US time.

BIO is the world's largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the United States and in 30+ countries. The BIO International Convention is the world's largest gathering of the biotechnology industry. It attracts more than 15,000 biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships.

New presentation material

Attached is a copy of the presentation that Dr Foster will present at the conference. New material includes Phase 1 data from SUNY Upstate and Walter Reed which will form the basis of Island's Phase 2 PEACH1 study control data and an update to the upcoming milestones slide. (Refer to ASX announcement dated 15 June 2022 for more information.)

Presentation details

Date and time:	Wednesday, 15 June, 2022 at 11:45am PDT
Conference:	BIO International Convention 2022
Room:	Live in Company Presentation Theater 4

One-on-one meetings are also being scheduled via the BIO partnering system or by contacting Island directly (details below).

Approved for release to the ASX by:

Dr Paul MacLeman

Executive Chairman

Island

Pharmaceuticals Ltd

[e-mail]

1 A Phase 2a, Randomized, Double blind, Placebo-controlled Study for the Prophylactic Examination of an Antiviral in a

Dengue Challenge Model

Island Pharmaceuticals Limited ACN 641 183 842 | Registered office: Suite 201, 697 Burke Rd, Camberwell VIC 3124, Australia Page 1 of 2

For personal use only

Investors and media, for further information, please contact:

Jane Lowe

IR Department

Mobile: [phone]

[e-mail]

About Island Pharmaceuticals

Island (ASX: ILA) is a mid-clinical-stage drug repurposing company, focused on the topical area of antiviraltherapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well- established safety profile, being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases. The Company is close to commencing a Phase 2a clinical trial in dengue-infected subjects.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible toobtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visitwww.islandpharmaceuticals.comfor more on Island.

Island Pharmaceuticals Limited ACN 641 183 842 | Registered office: Suite 201, 697 Burke Rd, Camberwell VIC 3124, Australia Page 2 of 2

only SOLVING URGENT

useVIRAL DISEASE THREATS

ersonal(ASX: ILA) BIO June 2022

DISCLAIMER

	This presentation has been prepared by Island Pharmaceuticals Limited	views on its future performance or condition. Actual results could differ	No representation, warranty or assurance (express or implied) is given or
	(ABN 641 183 842) (Company or Island Pharmaceuticals).	materially from those referred to in this presentation. You should note	made in relation to any forward-looking statement by any person
		that past performance of the Group is not and cannot be relied upon as	(including the Company). In particular, but without limitation, no
	Not an offer or financial product advice	an indicator of (and provides no guidance as to) future Group	representation, warranty or assurance (express or implied) is given that
	The Company is not licensed to provide financial product advice. This	performance.	the occurrence of the events expressed or implied in any forward
		looking statements in this presentation will actually occur. Actual
	presentation is not and should not be considered, and does not contain	Future performance	operations, results, performance or achievement may vary materially
	or purport to contain, an offer or an invitation to sell, or a solicitation of		from any projections and forward-looking statements and the
	an offer to buy, directly or indirectly any securities, to any person in any	This presentation contains certain "forward-looking statements". The	assumptions on which those statements are based. Any forward looking
	jurisdiction to whom or in which such offer or solicitation is unlawful nor	words "expect", "anticipate", "estimate", "intend", "believe", "guidance",	statements in this presentation speak only as of the date of this
	shall it (or any part of it), or the fact of its distribution, form the basis of,	"propose", "goals", "targets", "aims", "outlook", "forecasts", "should",	presentation.
	r be relied on in connection with or act as any inducement or	"could", "would", "may", "will", "predict", "plan" and other similar
	rec mmendation to enter into, any contract whatsoever relating to any	expressions are intended to identify forward-looking statements. Any	Subject to any continuing obligations under applicable law, the
only
	securities. This presentation is for information purposes only and is not a	indications of, and guidance on, future operating performance, earnings	Company disclaims any obligation or undertaking to provide any
	prospectus, product disclosure statement, pathfinder document for the	and financial position and performance are also forward-looking	updates or revisions to any forward-looking statements in this
use
	purposes of section 734(9) of the Australian Corporations Act 2001 (Cth)	statements. Forward-looking statements in this presentation include	presentation to reflect any change in expectations in relation to any
	(Corporations Act) or other offer document under Australian law or the	statements regarding the Company's future growth options, strategies	forward-looking statements or any change in events, conditions or
	law of any other jurisdiction. This presentation does not constitute an	and new products. Forward-looking statements, opinions and estimates	circumstances on which any such statement is based.
	invitation to apply for or purchase Securities and does not include any	provided in this presentation are based on assumptions and
	application form for Securities. This presentation does not constitute an	contingencies which are subject to change without notice, as are	Nothing in this presentation will under any circumstances create an
	advertisement for an offer or proposed offer of Securities. Neither this	statements about market and industry trends, which are based on	implication that there has been no change in the affairs of the Group
	presentation nor anything contained in it shall form the basis of any	interpretations of current market conditions.	since the date of this presentation.
	contract or commitment and it is not intended to induce or solicit any
	person to engage in, or refrain from engaging in, any transaction.	Forward-looking statements, including projections, guidance on future
	Nothing in this presentation constitutes legal, financial, tax or other	operations, earnings and estimates (if any), are provided as a general
ersonal	guide only and should not be relied upon as an indication or guarantee
	advice. Recipients of the presentation should conduct their own
	investigation, evaluation and analysis of the business and other data and	of future performance. No representation is given that the assumptions
	information set out in the presentation.	upon which forward looking statements may be based are reasonable.
		This presentation contains statements that are subject to risk factors
	Fi ancial data All dollar values are in Australian dollars ($ or A$) unless	associated with the Group's industry. These forward-looking statements
	otherwise stated. Any financial data in this presentation is unaudited.	may be affected by a range of variables which could cause actual results
	Past performance The operating and historical financial information	or trends to differ materially, including but not limited to earnings,
	given in this presentation is given for illustrative purposes only and	capital expenditure, cash flow and capital structure risks and general
	sh uld not be relied upon as (and is not) an indication of the Company's	business risks.
	ISLAND PHARMACEUTICALS LIMITED	2	INVESTOR PRESENTATION - JUNE 2022

Island Pharmaceuticals (ASX: ILA) is a mid clinical-stagedrug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases

ISLAND AT A GLANCE

only• Advancing lead drug ISLA-101 toward Phase 2 "PEACH"* clinical trial for the prevention of dengue fever

use• Dengue fever infects +390 million people each year. There is currently no pharmaceutical treatment for the disease and limited access to only one vaccine

• Major market potential treating mosquito-borne diseases, exacerbated by climate change

• Positive results in aggressive animal and human cellular models of dengue fever and Zika infections as well as data in a range of other flaviviruses

• Priority Review Voucher potential for ISLA-101 at the time of FDA approval. PRVs have recently sold for at or slightly above US$100m

• Pipeline expansion underway, targeting other viruses with significant unmet need and limited

	competition.		* PEACH: Phase 2a, randomized, double blind, placebo-
			controlled study for the Prophylactic Examination of an
			Antiviral in a Dengue Challenge Model.
	ISLAND PHARMACEUTICALS LIMITED	3	INVESTOR PRESENTATION - JUNE 2022
ersonal